
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

